Common questions about Remsima (FAQ)
Q: Are there specific age limits for who can or cannot use Remsima?
A: Official product information states that this medicine is approved for the treatment of certain conditions in children and adolescents aged 6 years and older. For older adults (65 years and over), regulatory documents advise close observation, as a higher incidence of serious infections has been observed in this population.
Q: Why is Remsima given as an infusion rather than a tablet or injection?
A: Remsima is a type of medicine known as a monoclonal antibody, which is a complex protein. Because the digestive system would likely break down this protein, it cannot be taken as a tablet. Therefore, it is administered either directly into the vein via an infusion or through a subcutaneous (under-the-skin) injection.
Q: Is it recommended to receive certain vaccinations, like the flu shot, while on Remsima?
A: Regulatory guidelines strongly advise against receiving live vaccines while on treatment, as this medicine affects the immune system. Official product information suggests that patients be brought up to date with non-live vaccines prior to initiating therapy.
Q: What does the clinical research say about the long-term safety of Remsima?
A: Long-term safety is addressed in official documents by noting potential serious risks, including the development of certain malignancies (cancers). The official prescribing information emphasizes the need for continued long-term safety monitoring for patients, particularly in the pediatric population.
Q: Why is Remsima often used alongside other medicines, such as methotrexate?
A: For the treatment of rheumatoid arthritis, regulatory documents state that this medicine is intended to be given at the same time as methotrexate. Available data suggests that using the two medicines together provides a better clinical response than using Remsima alone.
Q: What are the risks described for using Remsima during pregnancy or while breastfeeding?
A: Official information indicates that the drug crosses the placenta. Therefore, infants exposed in the womb may not be able to safely receive live vaccines for up to 12 months after birth. The medicine has been detected at low levels in breast milk, and the systemic exposure to the nursing infant is expected to be minimal.
Q: Can Remsima be given to patients with a past history of tuberculosis or hepatitis B?
A: Regulatory documents indicate that testing for latent tuberculosis (TB) and hepatitis B virus (HBV) infection is required prior to initiating treatment. If latent TB is found, official guidelines require that treatment for TB begins before administering Remsima. HBV carriers must also be monitored closely for potential viral reactivation.
Q: Does Remsima interact with common over-the-counter pain relievers?
A: Regulatory-supported interaction databases indicate a need for caution when using this medicine alongside certain common over-the-counter pain relievers, such as acetaminophen and celecoxib. Patients are generally directed to discuss the use of all over-the-counter products with their healthcare provider.
Q: How long does a Remsima infusion usually take?
A: The standard intravenous infusion is typically given over a period of 2 hours. For carefully selected adult patients who have successfully tolerated the initial infusions, the treatment may sometimes be given over a shorter period of not less than 1 hour during maintenance therapy.
Q: How quickly do patients usually start to notice the effects of Remsima?
A: Studies and official product information indicate that for conditions like rheumatoid arthritis, patients usually achieve a clinical response within 12 weeks of starting treatment. For ulcerative colitis, a clinical response is typically achieved within 14 weeks, following the first three initial doses.
Q: What typically happens if a patient misses or delays a scheduled infusion?
A: For certain conditions during maintenance therapy, re-administration can be considered if the signs of disease recur within 16 weeks of the last infusion. However, regulatory safety and efficacy data have not been established for re-administration after longer intervals.
Q: What types of vitamin or herbal supplements should be discussed before using Remsima?
A: Official interaction checkers caution that certain herbal supplements, such as astragalus and echinacea, may have documented interactions with this class of medicine. Official guidelines recommend that patients disclose the use of all supplements to their healthcare provider for a thorough review.
Q: Does Remsima contain any ingredients that commonly cause allergic reactions?
A: The formulation includes inactive ingredients such as Sorbitol and Polysorbate 80. Official product information states that the medicine should not be used if a patient has a known hypersensitivity (severe allergy) to the active substance or any of the inactive components.
Q: What should be done if a patient suspects an allergic reaction during an infusion?
A: Regulatory documents specify that patients should notify the administering nurse or doctor immediately if symptoms of an allergic reaction occur. Since the medicine can cause serious reactions, the infusion may need to be stopped if symptoms like a rash, chills, or difficulty breathing occur.
Q: Does Remsima have an official 'Black Box Warning' in its regulatory documents?
A: Yes, in the US, the product label includes a Boxed Warning—the most serious level of alert—issued by the FDA. This warning primarily concerns the increased risk of serious infections, including tuberculosis, and the potential for certain malignancies (cancers).
Q: Can Remsima affect a person's ability to drive or operate heavy machinery?
A: Regulatory documents note that the medicine may have a minor influence on the ability to drive, primarily due to the potential for dizziness. The official label notes that if a patient experiences tiredness, dizziness, or other effects that could impair their judgment, driving or operating heavy machinery is generally not recommended.
Q: What kind of monitoring (blood tests, etc.) is generally required while taking Remsima?
A: Close monitoring is required throughout treatment. This includes monitoring for infections (like TB and HBV reactivation) before starting the medicine, during therapy, and for a period of time after the last treatment.
Q: What are the inactive ingredients or preservatives found in Remsima?
A: The inactive ingredients listed in the formulations vary slightly by type (IV or SC). Ingredients include compounds such as sodium phosphate, sucrose, acetic acid, sodium acetate trihydrate, sorbitol, and polysorbate 80.
Q: How often is Remsima typically scheduled for maintenance treatment?
A: The schedule depends on the formulation and condition being treated. For the intravenous (IV) version, maintenance infusions are typically scheduled every 8 weeks. For the subcutaneous (SC) version, maintenance doses are generally scheduled every 2 weeks.
